Krka d. d - Asset Resilience Ratio
Krka d. d (KRK) has an Asset Resilience Ratio of 11.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Krka d. d's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Krka d. d to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Krka d. d's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Krka d. d market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł340.29 Million | 11.18% |
| Total Liquid Assets | zł340.29 Million | 11.18% |
Asset Resilience Insights
- Moderate Liquidity: Krka d. d has 11.18% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Krka d. d Industry Peers by Asset Resilience Ratio
Compare Krka d. d's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Northeast Pharmaceutical Group Co Ltd
SHE:000597 |
Drug Manufacturers - Specialty & Generic | 1.62% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Shandong Lukang Pharmaceutical Co Ltd
SHG:600789 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Krka d. d (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Krka d. d.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 8.46% | zł257.29 Million ≈ $70.81 Million |
zł3.04 Billion ≈ $837.38 Million |
-0.12pp |
| 2024-12-31 | 8.58% | zł244.34 Million ≈ $67.25 Million |
zł2.85 Billion ≈ $784.09 Million |
+6.04pp |
| 2023-12-31 | 2.53% | zł70.02 Million ≈ $19.27 Million |
zł2.76 Billion ≈ $760.77 Million |
+0.65pp |
| 2022-12-31 | 1.89% | zł50.70 Million ≈ $13.95 Million |
zł2.69 Billion ≈ $739.64 Million |
-4.18pp |
| 2021-12-31 | 6.07% | zł153.96 Million ≈ $42.37 Million |
zł2.54 Billion ≈ $698.41 Million |
+5.67pp |
| 2020-12-31 | 0.40% | zł8.97 Million ≈ $2.47 Million |
zł2.24 Billion ≈ $615.25 Million |
+0.30pp |
| 2019-12-31 | 0.10% | zł2.17 Million ≈ $598.32K |
zł2.18 Billion ≈ $601.24 Million |
-0.05pp |
| 2018-12-31 | 0.15% | zł2.92 Million ≈ $803.63K |
zł1.99 Billion ≈ $546.32 Million |
+0.64pp |
| 2017-12-31 | -0.50% | zł-9.54 Million ≈ $-2.63 Million |
zł1.92 Billion ≈ $528.17 Million |
-0.50pp |
| 2016-12-31 | 0.00% | zł77.00K ≈ $21.19K |
zł1.91 Billion ≈ $526.08 Million |
0.00pp |
| 2015-12-31 | 0.00% | zł79.00K ≈ $21.74K |
zł1.81 Billion ≈ $497.92 Million |
-0.03pp |
| 2014-12-31 | 0.03% | zł575.00K ≈ $158.25K |
zł1.80 Billion ≈ $494.21 Million |
-0.01pp |
| 2013-12-31 | 0.05% | zł792.00K ≈ $217.97K |
zł1.76 Billion ≈ $484.35 Million |
+0.00pp |
| 2012-12-31 | 0.04% | zł679.00K ≈ $186.87K |
zł1.63 Billion ≈ $447.70 Million |
+0.00pp |
| 2011-12-31 | 0.04% | zł602.00K ≈ $165.68K |
zł1.53 Billion ≈ $422.19 Million |
0.00pp |
| 2010-12-31 | 0.04% | zł653.00K ≈ $179.72K |
zł1.49 Billion ≈ $409.58 Million |
-- |
About Krka d. d
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, an… Read more